Jag Shur is the Chief Executive Officer of Nanopharm, an Aptar Pharma company. His main area of research is investigation of the bioequivalence of OINDPs. The key theme of his research has been the development and application of novel tools to understand and quantify the microstructure of OINDPs. He began his career with Profile Drug Delivery (now Philips Respironics) where he developed liquid dose drug delivery systems for cystic fibrosis patients, and later went on to work for GlaxoSmithKline. Dr Shur holds a BSc (Hons) in Chemistry, and completed his PhD at Portsmouth School of Pharmacy (UK). Following this, he was a post-doctoral fellow at the London School of Pharmacy (UK), investigating the fabrication of microparticles for vaccine delivery using supercritical fluid technology.